Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gender-related response to tyrosine kinase inhibitors in hepatocellular carcinoma
2019-003765-18Phase 4Terminated
- Sponsor
- DIPARTIMENTO AD ATTIVITÃ INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sorafenib and regorafenib in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by DIPARTIMENTO AD ATTIVITÃ INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE. Primary endpoints: Primary endpoint for part 1 and Primary endpoint for part 2. Started May 2021; status: terminated.
02
Drugs
sorafenibregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-003765-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003765-18.